Knowledge and utilization of malaria control measures by pregnant and newly delivered mothers in Ibadan, Nigeria

*Oladokun A¹, Oladokun RE², Adesina OA¹

- 1. Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, Nigeria
- 2. Department of Paediatrics, University College Hospital, Ibadan, Nigeria

Abstract

Background: The World Health Organisation (WHO) guidelines for the control of malaria during pregnancy include prompt and effective case management of malaria combined with prevention of infection by insecticide-treated nets (ITNs) and intermittent preventive treatment in pregnancy (IPTp). Despite this the uptake is poor.

Objective: To describe the malaria prevention measures utilized by these women in this environment.

Methods: Information was obtained from consented pregnant and newly delivered women on their socio-demographic characteristics, knowledge and use of malaria chemoprophylaxis

Results: One Thousand three hundred thirty (1330) pregnant and newly delivered women in 132 facilities within the Ibadan metropolis were surveyed. The mean age of the respondents was 29. 67 years (±5,21). The modes of prevention most commonly reported as being effective were the use of insecticide spray, window nets and ITN. Only 28.2% were using ITNs in the index pregnancy, and 67.2% of the women had had a drug administered for prophylactic purposes in the index pregnancy.

Conclusion: This study demonstrates awareness but poor use of control measures. Additionally, there is poor use of the recommended agent for IPT. The factors militating against the use of these preventive measures need to be urgently explored and addressed.

Key words: malaria in pregnancy, chemoprophylaxis, intermittent preventive therapy

African Health Sciences 2011; 11(4): 573 – 577

Introduction

Every year, approximately 50 million women living in malaria endemic areas become pregnant; half of them in sub-Saharan Africa, and many are in areas of intense plasmodium falciparum transmission¹ (p.falciparium). In these regions, malaria in pregnancy is predominantly asymptomatic and yet it is a major cause of severe maternal anaemia and low birthweight babies². Because of the strong association between low birth weight and child survival, successful control of malaria in pregnancy will not only save maternal lives but might also prevent 75 000–200 000 infant deaths every year³. It is thus of a high public health priority in all endemic countries.

*Correspondence author:

Dr. A. Oladokun Department of Obstetrics & Gynaecology College of Medicine University College Hospital Ibadan, Nigeria. Tel: 234 8033285279 sinaoladokun@yahoo.com,

oladokun@comui.edu.ng

For sub-Saharan Africa (SSA), the WHO has developed guidelines for the control of malaria during pregnancy². These consist of prompt and effective case management of malaria illness, combined with prevention of infection and/or disease by insecticide-treated nets and intermittent preventive treatment in pregnancy (IPTp).^{1,4}

A recent systematic review has shown that insecticide treated nets (ITNs) are beneficial to both mother and newborn baby in SSA⁵. Indeed, it is one of the main strategies of the Roll Back Malaria (RBM) partnership. The ITNs, compared with no nets, substantially reduce the risk of placental malaria and adverse pregnancy outcome such as low birth weight (LBW) and stillbirth/abortion. In addition, insecticide-treated nets that are provided to pregnant women have the added beneût that they continue to protect the newborn baby during infancy, since most babies sleep with their mothers.² At the household level, in addition to ITNs, other protective measures include protective clothing, insect repellents and spraying of insecticides.6

In sub-Saharan Africa, until the mid to late 1990s, prevention of malaria in pregnancy relied on weekly chloroquine prophylaxis.2 This mode of prevention, however, had the challenge of poor compliance.7 Intermittent preventive treatment in pregnancy was explored and developed to avoid limitations of daily or chemoprophylaxis.^{8,9} It consists of an antimalarial treatment given at regular intervals during pregnancy, regardless of malaria infection or disease. In areas of stable P. falciparum transmission, WHO recommends Sulphadoxine-Pyrimethamine (SP) combination on account of it being cheap, easy to administer (single dose), and safe in the second and third trimester. At least two doses are given from the second trimester onwards at least one month apart. 1

It was initially thought that a drug regimen based on a few supervised doses would overcome the compliance limitations of chemoprophylaxis. In addition, concomitant insecticide-treated net use might reduce the need or frequency of IPTp dosing. However, studies in countries where IPTp has been implemented for several years show that the uptake of a second dose is surprisingly poor. ^{1, 10} More operational research is needed to develop strategies to improve the uptake and effectiveness of this promising strategy.

The aim of the study was to assess the level of adherence to the Intermittent preventive treatment in pregnancy (IPTp) using the Sulphadoxine-Pyrimethamine (SP) combination as recommended for the pregnant mothers.

Methods

The study was a cross-sectional survey of 1330 consented pregnant and newly delivered mothers in one hundred and thirty-two (132) hospitals and maternity centres in Ibadan metropolis over a period of one year from April 2008 to April 2009.

Ethical approval for the study was obtained from the University of Ibadan/University College Hospital (UI/UCH) Health Research Ethics Committee (UI/IRC/07/0111)

A list of the registered government and private hospitals within Ibadan metropolis was obtained from the State Ministry of Health which contained the 132 hospitals and maternity centres. All the hospitals and maternity centres were sampled.

An average of 10 consecutively consented (written) pregnant and newly delivered mothers who

were in the hospitals and the maternity centres at the time of visit were recruited into the study.

Information obtained on the knowledge and utilization of malaria control and treatment in pregnancy after obtaining their consent was entered into Microsoft excel file and analysis done using SPSS 16 software package. Results are presented as frequency tables.

Results

During study period, 1330 pregnant and newly delivered women in 132 facilities within the Ibadan metropolis were surveyed. The mean age of the respondents was 29. 67 years (±5.21). Over sixty percent (62. 2%) of the women had had 6 or more years of formal education. Most of the women were Christians (65.2%), and of Yoruba tribe (78.9%). The primigravidae was the commonest parity reported. Slightly over one-third of the respondents were traders.

Table 1: Selected socio-demographic characteristics

Characteristics	Percentage %			
Age				
Range 14 – 52 years				
Mean 29.67 ± 5.21 years				
Educational Level				
None	4.8			
Primary	33.0			
Secondary	30.8			
Tertiary	31.4			
Religion				
Christianity	65.2			
Islam	34.4			
Others	0.4			
Tribe				
Yoruba	78.9			
Igbo	10.7			
Hausa	4.3			
Others	6.1			
Parity				
0	32.3			
1	21.2			
2	22.3			
3	14.0			
<u>></u> 4	10.2			
Occupation				
Traders	35.4			
Paid employment	31.3			
Housewives/unemployed	18.7			
students				
Others	14.6			

The modes of prevention most commonly reported as being effective for the prevention of malaria in pregnancy were the use of insecticide spray, window nets and ITNs. While about half of the respondents were aware of the concept of drug resistant parasites, less than one-third (29.2%) of the respondents were aware of a new government policy on the prevention of malaria in pregnancy.

Table 2: Awareness of modes of protection in pregnancy

Modes of protection in Pregnancy	Yes (%)	No (%)	Don't Know (%)
Agents to prevent mosquito bites			
Use of insecticide	63.5	15.6	20.9
Mosquito coils	33.6	41.3	25.1
Repellent cream	30.2	21.6	48.2
Herbal preparation	29.1	35.1	35.8
Window nets	68.0	18.2	13.8
Insecticide treated nets	69.5	8.8	21.7
Awareness of drug resistant malaria parasites	52.3	18.6	29.1
Awareness of government policy on malaria preven	tion29.2	70.8	
IPT in pregnancy			
Aimed at eradicating malaria in pregnancy	24.5	2.6	73.9
It reduces severity of malaria attack in pregna	ncy 23.8	2.8	73.4
All pregnant mothers should receive it	25.4	1.4	73.2

While only 28.6% of the respondents had ever used ITNs and a similar proportion (28.2%) were using ITNs in the index pregnancy, about two-thirds (67.2%) of the women had had a drug administered for prophylactic purposes in the index pregnancy. Of the patients who had had preventive drugs administered the commonest drug prescribed was the SP combination.

In response to the question asking if the respondent had received treatment on account of malaria in the index pregnancy only 1,041 (78.3%) responded. Of this only 48.8% (508) responded in the affirmative about having received malaria treatment in the index pregnancy.

Table 3: Protective measures utilized in pregnancy

	Yes (%) No (%)		Don't know (%)
Ever used ITN	28.6	71.4	
Currently using ITN	28.2	71.8	
Use of anti-malaria drugs in index pregnancy	67.2	30.7	2.1
Preventive drug administered	64.5		
Chloroquine	7.4	35.5	
Amodiaquine	3.4		
Halofantirine	0.5		
ACT	2.1		
Arthemether	1.7		
Pyrimethamine	0.6		
Proguanil	3.2		
SP	33.2		
Quinine	12.4		

Discussion

This study shows a disturbing gap between knowledge and practice. Although most of the women were aware of the protective nature of ITNs, it was observed that very few of them were actually using these ITNs. This finding is consistent with other reports from south-west Nigeria which showed that the majority of the people used screens and sprays to protect against malaria while the use of ITNs was poor.^{6,11} It has been proposed that since the cost of the net is often not affordable by the group particularly vulnerable to malaria and its

deleterious effects i.e. very young children and pregnant women, it may be ideal for the Federal Government of Nigeria to make ITNs available at a highly subsidized rate⁶.

In contrast to the poor usage rate of ITN, a large proportion of parturient women in this study received prophylactic drugs for malaria but disturbingly, over half of the drugs were not those currently recommended by the WHO or the Federal Ministry of Health i.e. sulphadoxine-pyrimethamine. This is in spite of the fact that Nigeria adopted the IPT strategy in year 2005^{12, 13}. The WHO expects 80% of all pregnant women living in areas of high transmission to receive IPTp during pregnancy by 2010¹⁴. However, the coverage of the intervention is still low. A similar scenario was seen in Kenya, one of the first countries to implement IPTp. Its national coverage for two doses of SP was only 4% five years after IPTp implementation^{13, 15.} Various reasons have been proffered for the poor adherence to this simple regimen. These reasons could be patient or health worker related¹³. In two Tanzanian studies, low compliance with the use of SP was partly attributed to health care providers' and users' fear of side effects of SP and their inadequate knowledge of the correct dose. Most respondents were said to have believed that antimalarial drug when taken during pregnancy could be harmful to the pregnant women and the unborn children¹⁶.

The most commonly prescribed drugs for treatment as reported by the women were chloroquine and SP. Again, this is in spite of the current National Malaria Treatment Guideline and Policy in Nigeria that recommends quinine for treatment of clinical malaria in all trimesters¹². Artemisinin based combination therapy (ACT) is recommended as second line agents in the second and third trimesters and may be used in the first trimester where there are no suitable alternatives^{12,13,17}. Quinine and ACTs did not feature prominently in the drugs reported by these women for treatment.

This study demonstrates awareness of vector control measures but poor use of these measures by these pregnant women. In addition, there is poor use of the recommended agent for IPTp. While the factors militating against the use of these preventive measures need to be urgently explored and addressed, the national malaria control unit through the health facilities may have to provide ITNs and SP free of charge.

Conclusion

The government not only needs to educate the public in general and pregnant women in particular on the current approach to the prevention and management of malaria in pregnancy but plausible interventions to address the gaps and deficiencies must be developed. All of these will contribute to the attainment of the MDGs of improving the health of mothers and new-borns.

Acknowledgement

This study received support from the Senate Research Grant of the University of Ibadan, Nigeria.

References

- 1. WHO. A strategic framework for malaria prevention and control during pregnancy in the African region. Geneva: World Health Organization, 2004: AFR/MAL.
- Clara Menéndez, Umberto D'Alessandro, Feiko O ter Kuile. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007; 7: 126–35
- 3. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. *Am J Trop Med Hyg* 2001; 64 (suppl 1–2): 28–35.
- 4. Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. *Lancet Infect Dis* 2007; 7: 118–25
- 5. Gamble C, Ekwaru JP, ter Kuile FO. Insecticidetreated nets for preventing malaria in pregnancy. *Cochrane Database Syst Rev* 2006; 2: CD003755.
- Yusuf OB, Dada-Adegbola HO, Ajayi IO & Falade CO Malaria prevention practices among mothers delivering in an urban hospital in southwest Nigeria J Vector Borne Dis 2008 Sept; 45:217–224
- Rukaria-Kaumbutho RM, Ojwang SB, Oyieke JB. Resistance to chloroquine therapy in pregnant women with malaria parasitemia. *Int J Gynaecol Obstet* 1996; 53: 235–41.
- 8. Verhoeû FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the eû ects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. *Ann Trop Med Parasitol* 1998; 92: 141–50.
- 9. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to

- prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. *Lancet* 1999; 353: 632–36.
- Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. Intermittent sulfadoxine-pyrimethamine in pregnancy: eûectiveness against malaria morbidity in Blantyre, Malawi, in 1997–99. Trans R Soc Trop Med Hyg 2000; 94: 549–53
- Dare OO, Badru OB. Promoting the use of insecticide treated materials at the community level: experience from the ITN-oriade initiative. *Intl Quart Commun Health Edu* 2001; 20(3): 281– 95.
- FMOH: National guidelines and strategies for malaria prevention and control during pregnancy. A publication of the Federal Ministry of Health, Nigeria; Malaria Control Programme, FMOH, Abuja; 2005.
- 13. Akinyele SO, falade CO, Ajayi IO Knowledge and utilization of intermittent preventive treatment for malaria among pregnant women attending antenatal clinics in primary health care centers in rural southwest, Nigeria: a cross-

- sectional study BMC Pregnancy and Childbirth 2009, 9:28 doi:10.1186/1471-2393-9-28
- 14. WHO: Global strategy plan 2005–2015. 2005 [http://www.roll backmalaria.org/forumV/docs/gsp_en.pdf]. World Health Organization, Geneva
- 15. Greenwood A, Menendez C, Alonso P, Jaffar S, Langerock P, Lulat S, Todd J, M'Boge B, Francis N, Greenwood B: Can malaria chemoprophylaxis be restricted to first pregnancies? *Trans R Soc Trop Med Hyg* 1994; 88:681-682
- 16. Mubyazi A, Bloch P, Kamugisha M, Kituua A, Ijimba J: Intermittent preventive treatment of malaria during pregnancy: A qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe district, Northern eastern Tanzania. *Malar J* 2005, 4:31.
- 17. Omo Aghoja IO, Aghoja CO, Oghagbon K, Omo Aghoja VW, Esume C: Prevention and treatment of malaria in pregnancy inNigeria: Obstetrician's knowledge of guidelines and policy changes a call for action. *Journal of Chinese clinical Medicine* 2008, 3:2.